Longeveron (LGVN) Competitors $1.64 +0.02 (+0.93%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.63 -0.01 (-0.31%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. ONCY, IPA, CLYM, PLRX, ABOS, IVVD, ADAG, ADAP, VIRI, and WHWKShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Oncolytics Biotech (ONCY), ImmunoPrecise Antibodies (IPA), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Acumen Pharmaceuticals (ABOS), Invivyd (IVVD), Adagene (ADAG), Adaptimmune Therapeutics (ADAP), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. Its Competitors Oncolytics Biotech ImmunoPrecise Antibodies Climb Bio Pliant Therapeutics Acumen Pharmaceuticals Invivyd Adagene Adaptimmune Therapeutics Virios Therapeutics Whitehawk Therapeutics Longeveron (NASDAQ:LGVN) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Does the media favor LGVN or ONCY? In the previous week, Oncolytics Biotech had 4 more articles in the media than Longeveron. MarketBeat recorded 5 mentions for Oncolytics Biotech and 1 mentions for Longeveron. Oncolytics Biotech's average media sentiment score of 0.20 beat Longeveron's score of -1.00 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Overall Sentiment Longeveron Negative Oncolytics Biotech Neutral Which has more risk and volatility, LGVN or ONCY? Longeveron has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Is LGVN or ONCY more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. Longeveron's return on equity of -85.07% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-760.72% -85.07% -70.74% Oncolytics Biotech N/A -313.77%-130.19% Do analysts rate LGVN or ONCY? Longeveron presently has a consensus target price of $8.67, suggesting a potential upside of 430.07%. Oncolytics Biotech has a consensus target price of $4.33, suggesting a potential upside of 337.71%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Oncolytics Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has higher valuation and earnings, LGVN or ONCY? Longeveron has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$2.39M10.21-$15.97M-$6.28-0.26Oncolytics BiotechN/AN/A-$23.14M-$0.29-3.41 Do insiders and institutionals have more ownership in LGVN or ONCY? 10.0% of Longeveron shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 11.2% of Longeveron shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryLongeveron beats Oncolytics Biotech on 10 of the 15 factors compared between the two stocks. Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.18M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.2617.7428.8623.83Price / Sales10.21178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book1.118.508.275.54Net Income-$15.97M-$55.06M$3.25B$259.28M7 Day Performance-2.10%-3.99%-3.73%-4.68%1 Month Performance25.77%9.58%4.29%4.36%1 Year Performance-43.43%6.70%25.87%17.89% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron2.2893 of 5 stars$1.64+0.9%$8.67+430.1%-46.2%$24.18M$2.39M-0.2620Negative NewsShort Interest ↑Gap DownONCYOncolytics Biotech2.4595 of 5 stars$1.09+3.8%$4.33+297.6%-3.9%$99MN/A-3.7630Upcoming EarningsIPAImmunoPrecise Antibodies2.0366 of 5 stars$2.02-6.5%$4.00+98.0%+90.0%$98.85M$24.00M-1.7480News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpCLYMClimb Bio2.3411 of 5 stars$1.60+10.3%$9.00+462.5%N/A$97.99MN/A-0.679Positive NewsHigh Trading VolumePLRXPliant Therapeutics3.6413 of 5 stars$1.59+1.3%$13.31+737.3%-89.0%$96.38M$1.58M-0.4490Upcoming EarningsABOSAcumen Pharmaceuticals2.5697 of 5 stars$1.46-7.0%$6.33+333.8%-58.2%$95.10MN/A-0.7520Positive NewsIVVDInvivyd3.0025 of 5 stars$0.84+6.7%$5.85+598.7%-38.7%$94.17M$25.38M-0.70100ADAGAdagene2.5258 of 5 stars$1.99-0.2%$8.00+302.8%-25.9%$93.75M$100K0.00260Positive NewsADAPAdaptimmune Therapeutics2.4959 of 5 stars$0.10-71.2%$1.35+1,251.7%-93.7%$91.95M$178.03M-0.37490News CoverageAnalyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeVIRIVirios TherapeuticsN/A$4.77+0.8%$5.00+4.8%+2,247.1%$91.86MN/A-17.675Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.81-7.2%N/AN/A$91.86M$25.98M11.3140 Related Companies and Tools Related Companies ONCY Alternatives IPA Alternatives CLYM Alternatives PLRX Alternatives ABOS Alternatives IVVD Alternatives ADAG Alternatives ADAP Alternatives VIRI Alternatives WHWK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
